



## Quarterly Cashflow Report

**Melbourne; 31 October 2008:** Attached is the Appendix 4C – Quarterly Cash Flow Report – for Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHY) for the quarter ended 30 September 2008.

Net cash decrease for the quarter was A\$1.3M, and at the end of the quarter the Company held cash reserves of A\$6.2 million.

Receipts of A\$1.5 million for the quarter included grant and contract payments from the U.S. National Institutes of Health (NIH) for VivaGel<sup>®</sup> development costs, together with other grant payments, and royalties from DNT technology.

---

### About Starpharma:

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel<sup>®</sup> (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

In the wider pharmaceutical field Starpharma has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells). More broadly the company is exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

SPL has a comprehensive IP portfolio with around 200 patents granted and applications pending - a unique level of IP concentration among nanotechnology companies.

**Dendrimers:** A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

**American Depositary Receipts (ADRs):** Starpharma's ADRs trade under the code SPHY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). The Bank of New York Mellon is the depository bank. Starpharma's ADRs are listed on International OTCQX ([www.otcqx.com](http://www.otcqx.com)), a premium market tier in the U.S. for international exchange-listed companies, operated by Pink OTC Markets, Inc.

### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

### For further information:

Media Buchan Consulting		Starpharma <a href="http://www.starpharma.com">www.starpharma.com</a>	
<b>Rebecca Wilson</b> Tel: +61 2 9237 2800 Mob: +61 417 382 391 <a href="mailto:rwilson@bcg.com.au">rwilson@bcg.com.au</a>	<b>Ellie Papathanasiou</b> Tel: +61 2 9237 2800 <a href="mailto:epapathanasiou@bcg.com.au">epapathanasiou@bcg.com.au</a>	<b>Dr Jackie Fairley</b> Chief Executive Officer +61 3 8532 2704	<b>Ben Rogers</b> Company Secretary +61 3 8532 2702 <a href="mailto:ben.rogers@starpharma.com">ben.rogers@starpharma.com</a>

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Name of entity

<b>Starpharma Holdings Limited</b>
------------------------------------

ABN

<b>20 078 532 180</b>
-----------------------

Quarter ended ("current quarter")

<b>30 September 2008</b>
--------------------------

### Consolidated statement of cash flows

#### Cash flows related to operating activities

	Current Quarter \$A'000	Year to Date \$A'000
1.1 Receipts from customers	1,464	1,464
1.2 Payments for		
(a) staff costs	(1,450)	(1,450)
(b) advertising and marketing	(5)	(5)
(c) research and development	(1,810)	(1,810)
(d) leased assets	(33)	(33)
(e) other working capital	-	-
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	27	27
1.5 Interest and other costs of finance paid	(8)	(8)
1.6 Income taxes paid	-	-
1.7 Other	-	-
<b>Net operating cash flows</b>	<b>(1,815)</b>	<b>(1,815)</b>

#### Cash flows related to investing activities

1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(29)	(29)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other	-	-
<b>Net investing cash flows</b>	<b>(29)</b>	<b>(29)</b>
1.14 <b>Total operating and investing cash flows</b>	<b>(1,844)</b>	<b>(1,844)</b>

#### Cash flows related to financing activities

1.15 Proceeds from issues of shares	-	-
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Other	-	-
<b>Net financing cash flows</b>	<b>-</b>	<b>-</b>
<b>Net increase (decrease) in cash held</b>	<b>(1,844)</b>	<b>(1,844)</b>
1.21 Cash at beginning of quarter/year to date	7,482	7,482
1.22 Exchange rate adjustments	591	591
1.23 <b>Cash at end of quarter</b>	<b>6,229</b>	<b>6,229</b>

**Payments to directors of the entity and associates of the directors**  
**Payments to related entities of the entity and associates of the related entities**

	Current quarter \$A'000
1.24 Aggregate amount of payments to the parties included in item 1.2	(248)
1.25 Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Item 1.24 consists of the following:

(a) Remuneration paid to the Chief Executive Officer.

(b) Director's fees paid to non-executive directors.

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Nil

**Financing facilities available**

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities - Lease facility for laboratory equipment	682	658
3.2 Credit standby arrangements - Credit card facility	140	9

Item 3.1 A \$481,878 lease facility guaranteed by term deposit and a \$200,000 master asset finance facility with National Australia Bank for laboratory equipment.

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	3,354	4,506
4.2 Deposits at call	2,875	2,976
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter (item 1.23)</b>	<b>6,229</b>	<b>7,482</b>

## Acquisitions and disposals of business entities

- 5.1 Name of entity
- 5.2 Place of incorporation or registration
- 5.3 Consideration for acquisition or disposal
- 5.4 Total net assets
- 5.5 Nature of business

Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
-	-
-	-
-	-
-	-
-	-

## Compliance statement

1. This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Law (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
  
2. This statement does give a true and fair view of the matters disclosed.



31st October 2008

B P Rogers  
Company Secretary